RBC Capital analyst Brian Abrahams downgraded Incyte to Sector Perform from Outperform with a price target of $79, down from $81.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on INCY:
- Incyte management to meet with Oppenheimer
- Incyte granted orphan status for myelofibrosis treatment
- Incyte announces Japanese MHLW approval of Pemazyre
- Incyte upgraded to Market Perform at SVB after ruxolitinib XR CRL, Zynz approval
- Incyte upgraded to Market Perform from Underperform at SVB Securities
Questions or Comments about the article? Write to editor@tipranks.com